Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Stage/Subtype:  stage IV prostate cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 109 for your search:
Start Over
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ANZUP1303, NCI-2015-01658, ACTRN12614000126617, NCT02446444
An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR106935, NCI-2016-00117, NCT02531516
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR107614, NCI-2016-00191, 2015-000735-32, 56021927PCR3002, NCT02489318
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 9785-CL-0335, NCI-2016-00640, 2015-003869-28, NCT02677896
Zoptarelin Doxorubicin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 4P-09-9, NCI-2009-01418, NCT01240629
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Cabozantinib-S-Malate, Docetaxel, and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9243, NCI-2013-01554, 120204, P11901, 12-C-0204, NCT01683994
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Enzalutamide and Mifepristone in Treating Patients with Metastatic Hormone Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: IRB13-0979, NCI-2013-02151, CDMRP-PC121149, NCT02012296
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS142-03, NCI-2015-02095, NCT02325557
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ASN001-101, NCI-2015-01712, NCT02349139
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
Sirolimus, Docetaxel, and Carboplatin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9388, NCI-2015-01478, NCT02565901
Enzalutamide and Cabazitaxel in Treating Patients with Metastatic, Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB00011227, NCI-2015-01103, 11227, CRS00001390, NCT02522715
Ribociclib, Docetaxel. and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 145515, NCI-2015-01797, 15-15745, NCI-2015-01701, CLEE011XUS07T, NCT02494921
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EPI-506-CS-0001, NCI-2015-02044, NCT02606123
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GS-US-350-1604, NCI-2016-00521, 2015-003741-26, NCT02607228
Enzalutamide with or without Ribociclib in Treating Patients with Metastatic Hormone-Resistant, Chemotherapy Naïve Prostate Cancer That Retains Retinoblastoma Expression
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15G.322, NCI-2015-01454, c15-153, 2015-055, CLEE011XUS12T, OHR-8, NCT02555189
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: J07122, NCI-2010-02020, JHOC-J07122, JHOC-NA_00010227, NCT00670046
Hsp90 inhibitor STA-9090 With or Without Dutasteride in Treating Patients With Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-333, NCI-2011-00909, NCT01368003
Antiandrogen Therapy with or without Axitinib before Surgery in Treating Patients with Previously Untreated Prostate Cancer with Known or Suspected Lymph Node Metastasis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: 2011-0231, NCI-2015-01711, NCI-2011-02749, NCT01409200
Start Over